mariPOC® COVID-19 rapid tests
Our coronavirus test is the most accurate antigen rapid test currently available. It is based on the recognition of the SARS-CoV-2 viral nucleoprotein, and the results are obtained within 20 minutes to 2 hours.
mariPOC COVID-19 test is performed in the bench-top automated mariPOC test system, enabling analysis at the point of sampling. Thanks to its unique features, mariPOC SARS-CoV-2 test provides the best accuracy in results, while offering a very handy and quick procedure, for both patients and users.
Detecting the presence of the SARS coronavirus 2 is very simple and quick with mariPOC. Simply visit the closest healthcare centre and obtain your result while waiting. The extensive syndromic panel test will also identify other diseases such as influenza without any additional effort and with minimal expense.
Easy work flow
Typically, the sampling is done by taking a flocked swab sample from the nasopharynx. Alternatively, a nasal swab sample can be used. Sample pretreatment is easy and done safely in a closed primary container. The hands-on-time prior to automated analysis is very short.
- 20 minutes: > 90% of positive samples are reported, allowing making quarantine and clinical decisions without delay.
- 55 minutes to 2 hours: Low positive and negative results are reported
For more information, see our mariPOC COVID-19 rapid test brochure.
| Key features | ||||
|---|---|---|---|---|
| Automated simple-to-use test system | Different test panels for every need | Most infection spreaders detected in 20 minutes | 300 tests/day at the site of sampling | Detects different virus variants |
Test selection
Test plates including COVID-19 tests
| REF | |||
|---|---|---|---|
| 1184M | mariPOC Respi+ | Respi+, Quick Flu+ | 22 |
| 1194M | mariPOC RTI combi+ | Respi+ or Quick Flu+ and Pharyn or Quick StrepA | 22 + 22 |
| 1204S | mariPOC SARS-CoV-2 | SARS-CoV-2 | 308 |
| 1214M | mariPOC Quick combi+ | Quick Flu+ and Quick StrepA | 22 + 22 |
| 1224M | mariPOC Quick Flu+ | Quick Flu+ | 44 |
mariPOC tests are designed to target conservative regions of viruses and bacteria making them robust against seasonal and regional strain variations. The test for SARS-CoV-2 targets nucleoprotein (NP). mariPOC SARS-COV-2 test method detects all variants of concern currently recognised by the WHO. The test method has detected well the Delta variant (“Indian” variant, B.1.617) based on our research data from collaborating European University Hospital. Furthermore, the antibody reagents have been studied and proved to recognize Alpha variant (“UK variant”, B.1.1.7), Beta variant (“South Africa variant”), Gamma variant (“Brazil variant”), Delta variant (B.1.617) and Omicron variant (B.1.1.529).
Scientific data shows that the test detects SARS-CoV-2 also one day before the onset of symptoms and up to day 14 from the onset of symptoms, but only for as long as the individual is contagious.
mariPOC antigen tests are negative in the non-contagious phase whereas PCR tests can be long positive despite the person is no longer able to transmit the disease.
A comprehensive diagnostic solution for pandemic management
Watch the video below to see why mariPOC tests are particularly well suited for pandemic management.
mariPOC solutions are suitable, for example, for passenger testing, event testing and companies whose employees are unable to work remotely, such as on construction sites, factories and shipyards.
